BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+27.29%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.31B
AUM Growth
+$6.31B
(+17%)
Cap. Flow
-$8.53M
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
41.19%
Holding
231
New
21
Increased
88
Reduced
44
Closed
16
Top Buys
| 1 |
Bristol-Myers Squibb
BMY
|
$74M |
| 2 |
Charles River Laboratories
CRL
|
$42M |
| 3 |
Abbott
ABT
|
$19.7M |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
$18.1M |
| 5 |
Arvinas
ARVN
|
$17.9M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$108M |
| 2 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$84.8M |
| 3 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$84.7M |
| 4 |
Gilead Sciences
GILD
|
$35.3M |
| 5 |
Teladoc Health
TDOC
|
$32.6M |
Sector Composition
| 1 | Healthcare | 95.59% |
| 2 | Industrials | 0.45% |
| 3 | Technology | 0.42% |
| 4 | Communication Services | 0.09% |
| 5 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $509M | 8.08% | 8,431,820 +109,906 | +1% | +$6.64M |
|
2
Neurocrine Biosciences
NBIX
$13.8B
| $357M | 5.66% | 3,318,374 +19,900 | +0.6% | +$2.14M |
|
3
Incyte
INCY
$16.5B
| $307M | 4.87% | 3,517,000 -179,200 | -5% | -$15.6M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $304M | 4.82% | 1,389,289 -39,850 | -3% | -$8.73M |
|
5
Esperion Therapeutics
ESPR
$448M
| $270M | 4.28% | 4,525,010 +283,549 | +7% | +$16.9M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $215M | 3.41% | 1,864,783 -100,289 | -5% | -$11.6M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $187M | 2.97% | 3,924,954 +353,400 | +10% | +$16.9M |
|
8
argenx
ARGX
$43.6B
| $156M | 2.47% | 967,989 -5,250 | -0.5% | -$846K |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $150M | 2.38% | 1,388,928 +22,400 | +2% | +$2.42M |
|
10
Halozyme
HALO
$8.56B
| $142M | 2.26% | 8,036,856 +22,500 | +0.3% | +$399K |
|
|
RDUS
11
DELISTED
Radius Health, Inc.
RDUS
| $140M | 2.22% | 6,942,385 +65,500 | +1% | +$1.32M |
|
|
12
Bristol-Myers Squibb
BMY
$96B
| $134M | 2.13% | 2,089,242 +1,152,233 | +123% | +$74M |
|
|
13
Abbott
ABT
$231B
| $115M | 1.83% | 1,325,420 +227,306 | +21% | +$19.7M |
|
14
Intuitive Surgical
ISRG
$170B
| $104M | 1.65% | 176,276 +631 | +0.4% | +$373K |
|
15
Elevance Health
ELV
$71.8B
| $98.2M | 1.56% | 325,174 +19,068 | +6% | +$5.76M |
|
16
Moderna
MRNA
$9.37B
| $96.5M | 1.53% | 4,935,081 +91,000 | +2% | +$1.78M |
|
17
Medtronic
MDT
$119B
| $96.2M | 1.53% | 848,330 +40,692 | +5% | +$4.62M |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $95.2M | 1.51% | 1,306,313 +13,800 | +1% | +$1.01M |
|
|
SAGE
19
DELISTED
Sage Therapeutics
SAGE
| $94.5M | 1.5% | 1,308,854 +5,350 | +0.4% | +$386K |
|
|
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $88.6M | 1.41% | 715,176 +13,000 | +2% | +$1.61M |
|
21
Humana
HUM
$36.5B
| $83.4M | 1.32% | 227,447 -15,226 | -6% | -$5.58M |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $81.2M | 1.29% | 2,366,000 -222,990 | -9% | -$7.65M |
|
23
UnitedHealth
UNH
$281B
| $80.9M | 1.28% | 275,210 +36,498 | +15% | +$10.7M |
|
24
Align Technology
ALGN
$10.3B
| $77.8M | 1.23% | 278,703 -59,780 | -18% | -$16.7M |
|
|
MYOV
25
DELISTED
Myovant Sciences Ltd.
MYOV
| $74.7M | 1.18% | 4,815,109 | – | – |
|